These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

336 related items for PubMed ID: 15654581

  • 21. Bone mass response to discontinuation of long-term hormone replacement therapy: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) Safety Follow-up Study.
    Greendale GA, Espeland M, Slone S, Marcus R, Barrett-Connor E, PEPI Safety Follow-Up Study (PSFS) Investigators.
    Arch Intern Med; 2002 Mar 25; 162(6):665-72. PubMed ID: 11911720
    [Abstract] [Full Text] [Related]

  • 22. Changes in bone density and turnover after alendronate or estrogen withdrawal.
    Wasnich RD, Bagger YZ, Hosking DJ, McClung MR, Wu M, Mantz AM, Yates JJ, Ross PD, Alexandersen P, Ravn P, Christiansen C, Santora AC, Early Postmenopausal Intervention Cohort Study Group.
    Menopause; 2004 Mar 25; 11(6 Pt 1):622-30. PubMed ID: 15545790
    [Abstract] [Full Text] [Related]

  • 23. CE/BZA effects on bone and quality of life in European postmenopausal women: a pooled analysis.
    Hadji P, Ryan KA, Yu CR, Mirkin S, Komm BS.
    Climacteric; 2016 Oct 25; 19(5):482-7. PubMed ID: 27631562
    [Abstract] [Full Text] [Related]

  • 24. Randomized trial comparing low-dose hormone replacement therapy and HRT plus 1alpha-OH-vitamin D3 (alfacalcidol) for treatment of postmenopausal bone loss.
    Mizunuma H, Shiraki M, Shintani M, Gorai I, Makita K, Itoga S, Mochizuki Y, Mogi H, Iwaoki Y, Kosha S, Yasui T, Ishihara O, Kurabayashi T, Kasuga Y, Hayashi K.
    J Bone Miner Metab; 2006 Oct 25; 24(1):11-5. PubMed ID: 16369892
    [Abstract] [Full Text] [Related]

  • 25. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group.
    Hosking D, Chilvers CE, Christiansen C, Ravn P, Wasnich R, Ross P, McClung M, Balske A, Thompson D, Daley M, Yates AJ.
    N Engl J Med; 1998 Feb 19; 338(8):485-92. PubMed ID: 9443925
    [Abstract] [Full Text] [Related]

  • 26. How many women lose bone mineral density while taking hormone replacement therapy? Results from the Postmenopausal Estrogen/Progestin Interventions Trial.
    Greendale GA, Wells B, Marcus R, Barrett-Connor E.
    Arch Intern Med; 2000 Nov 13; 160(20):3065-71. PubMed ID: 11074735
    [Abstract] [Full Text] [Related]

  • 27. Body composition during treatment with conjugated estrogens with and without medroxyprogesterone acetate: analysis of the women's Health, Osteoporosis, Progestin, Estrogen (HOPE) trial.
    Thorneycroft IH, Lindsay R, Pickar JH.
    Am J Obstet Gynecol; 2007 Aug 13; 197(2):137.e1-7. PubMed ID: 17689624
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women.
    Murphy MG, Weiss S, McClung M, Schnitzer T, Cerchio K, Connor J, Krupa D, Gertz BJ, MK-677/Alendronate Study Group.
    J Clin Endocrinol Metab; 2001 Mar 13; 86(3):1116-25. PubMed ID: 11238495
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. HRT and exercise: effects on bone density, muscle strength and lipid metabolism. A placebo controlled 2-year prospective trial on two estrogen-progestin regimens in healthy postmenopausal women.
    Heikkinen J, Kyllönen E, Kurttila-Matero E, Wilén-Rosenqvist G, Lankinen KS, Rita H, Väänänen HK.
    Maturitas; 1997 Mar 13; 26(2):139-49. PubMed ID: 9089564
    [Abstract] [Full Text] [Related]

  • 32. Combination therapy with hormone replacement and alendronate for prevention of bone loss in elderly women: a randomized controlled trial.
    Greenspan SL, Resnick NM, Parker RA.
    JAMA; 2003 May 21; 289(19):2525-33. PubMed ID: 12759324
    [Abstract] [Full Text] [Related]

  • 33. Endometrial effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate: two-year substudy results.
    Pickar JH, Yeh IT, Wheeler JE, Cunnane MF, Speroff L.
    Fertil Steril; 2003 Nov 21; 80(5):1234-40. PubMed ID: 14607581
    [Abstract] [Full Text] [Related]

  • 34. Ethnic differences in levels of bone and cartilage biomarkers and hormonal responsiveness in nine groups of postmenopausal Asian women: the Pan-Asia Menopause (PAM) study.
    Holinka CF, Christiansen C, Tian XW, Ausmanas MK.
    Climacteric; 2008 Feb 21; 11(1):44-54. PubMed ID: 18202964
    [Abstract] [Full Text] [Related]

  • 35. Endometrial effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate.
    Pickar JH, Yeh I, Wheeler JE, Cunnane MF, Speroff L.
    Fertil Steril; 2001 Jul 21; 76(1):25-31. PubMed ID: 11438315
    [Abstract] [Full Text] [Related]

  • 36. Bone mineral density response to estrogen replacement in frail elderly women: a randomized controlled trial.
    Villareal DT, Binder EF, Williams DB, Schechtman KB, Yarasheski KE, Kohrt WM.
    JAMA; 2001 Aug 15; 286(7):815-20. PubMed ID: 11497535
    [Abstract] [Full Text] [Related]

  • 37. Prevention of bone loss by clodronate in early postmenopausal women with vertebral osteopenia: a dose-finding study.
    Välimäki MJ, Laitinen K, Patronen A, Puolijoki H, Seppänen J, Pylkkänen L, Aranko SM, Sairanen S, Blåfield H, Rekiaro M, Väisänen K, Kormano M, Mäkinen L, Salmi J, Ala-Kaila K, Perttilä J, Vesterinen K, Koivunoro K, Probone Study Group.
    Osteoporos Int; 2002 Dec 15; 13(12):937-47. PubMed ID: 12459936
    [Abstract] [Full Text] [Related]

  • 38. Intravenous ibandronate injections given every three months: a new treatment option to prevent bone loss in postmenopausal women.
    Stakkestad JA, Benevolenskaya LI, Stepan JJ, Skag A, Nordby A, Oefjord E, Burdeska A, Jonkanski I, Mahoney P, Ibandronate Intravenous Study Group.
    Ann Rheum Dis; 2003 Oct 15; 62(10):969-75. PubMed ID: 12972476
    [Abstract] [Full Text] [Related]

  • 39. Effects of hormone replacement therapy on bone mineral density in postmenopausal women with primary hyperparathyroidism: four-year follow-up and comparison with healthy postmenopausal women.
    Orr-Walker BJ, Evans MC, Clearwater JM, Horne A, Grey AB, Reid IR.
    Arch Intern Med; 2000 Jul 24; 160(14):2161-6. PubMed ID: 10904459
    [Abstract] [Full Text] [Related]

  • 40. Hormone replacement therapy in women with epilepsy: a randomized, double-blind, placebo-controlled study.
    Harden CL, Herzog AG, Nikolov BG, Koppel BS, Christos PJ, Fowler K, Labar DR, Hauser WA.
    Epilepsia; 2006 Sep 24; 47(9):1447-51. PubMed ID: 16981859
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.